Sage Journals: Discover world-class research

Abstract

Background:

No molecular marker can monitor disease progression and treatment efficacy in multiple sclerosis (MS). Circulating microparticles represent a potential snapshot of disease activity at the blood brain barrier.

Objectives and methods:

To profile plasma microparticles by flow cytometry in MS and determine how fingolimod could impact endothelial microparticles production.

Results:

In non-treated MS patients compared to healthy and fingolimod-treated patients, endothelial microparticles were higher, while B-cell-microparticle numbers were lower. Fingolimod dramatically reduced tumour necrosis factor (TNF)-induced endothelial microparticle release in vitro.

Conclusion:

Fingolimod restored dysregulated endothelial and B-cell-microparticle numbers, which could serve as a biomarker in MS.

Keywords

Multiple sclerosis immunology plasma microparticles vascular endothelium B cells fingolimod biological marker

Get full access to this article

View all access options for this article.

References

Combes

Simon

Grau

. et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104: 93–102.

Chofflon

Roth

Juillard

. et al. Tumor necrosis factor production capacity as a potentially useful parameter to monitor disease activity in multiple sclerosis. Eur Cytokine Netw 1997; 8: 253–257.

Schindler

Little

Klegeris

. Microparticles: A new perspective in central nervous system disorders. Biomed Res Int 2014; 2014: 756327.

Minagar

Jimenez

. et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 2001; 56: 1319–1324.

Marcos-Ramiro

Oliva Nacarino

Serrano-Pertierra

. et al. Microparticles in multiple sclerosis and clinically isolated syndrome: Effect on endothelial barrier function. BMC Neurosci 2014; 15: 110.

Minagar

Jimenez

. et al. Endothelial microparticles (EMP) bind and activate monocytes: Elevated EMP-monocyte conjugates in multiple sclerosis. Front Biosci 2004; 9: 3137–3144.

Jimenez

Mauro

. et al. Elevated endothelial microparticle-monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-beta 1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes. Mult Scler 2005; 11: 310–315.

Pankoui Mfonkeu

Gouado

Fotso Kuate

. et al. Elevated cell-specific microparticles are a biological marker for cerebral dysfunctions in human severe malaria. PLoS ONE 2010; 5: e13415.

Latham

Tiberti

Gokoolparsadh

. et al. Immuno-analysis of microparticles: Probing at the limits of detection. Sci Rep 2015; 5: 16314.

10.

Latham

Chaponnier

Dugina

. et al. Cooperation between beta- and gamma-cytoplasmic actins in the mechanical regulation of endothelial microparticle formation. FASEB J 2013; 27: 672–683.

11.

Alexander

Chervenak

Weinstock-Guttman

. et al. Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes. J Neurol Sci 2015; 355: 84–89.

12.

Saenz-Cuesta

Irizar

Castillo-Trivino

. et al. Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis. Biomark Med 2014; 8: 653–661.

13.

Faille

Combes

Mitchell

. et al. Platelet microparticles: A new player in malaria parasite cytoadherence to human brain endothelium. FASEB J 2009; 23: 3449–3458.

Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients

Abstract

Background:

Objectives and methods:

Results:

Conclusion:

Keywords

Get full access to this article

References